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Abstract We analyzed the rate of polymyalgia rheumatica
(PMR) and remitting seronegative symmetrical synovitis
with pitting edema (RS3PE) syndrome, both characterized
as seronegative inXammatory arthritis in elderly, in an out-
patient unit where primary care physicians are working in
Japan to better understand the epidemiological characteris-
tics of the diseases in Japan. Consecutive outpatients who
newly visited at Department of General Medicine, Asahik-
awa Medical University Hospital, Japan, between April
2004 and March 2010 were analyzed. Each parameter such
as age, sex, diagnosis, and biochemical examination was
investigated. During the 6 years, 10 or 3 patients were diag-
nosed as PMR or RS3PE syndrome, respectively. The
patients with PMR were 7 women and 3 men, and the aver-
age age at diagnosis was 69. Out of all patients aged over
50 (n = 3,347), the rate of PMR was 0.22% in men or
0.36% in women, respectively. On the other hand, RS3PE
syndrome was diagnosed in 3 men (76, 76, and 81 years
old). The rate of patients with RS3PE syndrome was 0.09%
among outpatients aged over 50 indicating that the rate of
PMR in an outpatient clinic in Japan is not far from previ-
ous  Wndings reported from western countries. When
compared with PMR, the rate of RS3PE syndrome was
approximately one-third, providing for the Wrst time the rate
of RS3PE syndrome when compared with PMR. These epi-
demilogical data might help us pick up the diseases in pri-
mary care setting in Japan.
Keywords Polymyalgia rheumatica (PMR) · Remitting 
seronegative symmetrical synovitis with pitting edema 
(RS3PE) syndrome · Primary care · Japan · Epidemiology
Introduction
Polymyalgia rheumatica (PMR) is one of the most wide-
spread inXammatory rheumatic disease aVecting people
aged over 50 and characterized by pain and morning stiV-
ness in the neck, shoulder, and pelvic girdle [1]. PMR is
generally regarded as a benign disease with no adverse
impact on long-term survival [2, 3] and represents one of
the most common indicators for long-term steroid therapy
in the community [4, 5]. Patients with PMR are subjected to
wide variations in clinical practice and may be managed in
primary or secondary care by general practitioners [6, 7]. A
couple of studies demonstrated the prevalence of PMR in
USA and Canada [8–10]. With regard to the reports on
PMR in Japan, there are some clinical studies on patients
with PMR. For example, Wve independent research groups
demonstrated clinical features in 29, 13, 7, 44, or 32
patients with PMR in Japan, respectively [11–15]. Thus,
PMR is observed commonly in Japan. However, the preva-
lence of the disease is not so far known.
Increasing evidence has suggested that remitting sero-
negative symmetrical synovitis with pitting edema
(RS3PE) syndrome is also one of the inXammatory rheu-
matic disease of the elderly [16]. RS3PE was described in
1985 by McCarty et al. as an original subgroup of seroneg-
ative rheumatoid arthritis [17]. It occurred especially in
men older than 60. The onset of the disease was sudden and
characterized by a symmetrical polyarthritis associated
with pitting edema of the extremities of the upper and lower
limbs. According to the report by Olivieri et al. [16], the
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following diagnostic criteria for this syndrome had been
proposed. These include the following: (1) bilateral pitting
edema of both hands, (2) sudden onset of polyarthritis, (3)
age more than 50, and (4) seronegative rheumatoid factor.
So far, there are some papers that show patients with
RS3PE syndrome in Japan. A couple of independent
research groups have demonstrated 7, 13, 11, or 3 Japanese
patients with RS3PE syndrome [18–21]. Thus, RS3PE syn-
drome is not very rare in Japan. However, the prevalence of
the disease in Japan is not known. Thus, little is known
about the epidemiologic feature in patients with PMR and
RS3PE syndrome, both characterized as seronegative
inXammatory arthritis in elderly [1, 17]. According to the
study by Kremers [7], generalists provide the majority of
care for patients with PMR. Rheumatologist involvement is
generally limited to diagnostic conWrmation and manage-
ment of complications. Thus, primary care physicians have
to pay attention to accurately diagnose PMR in the daily
practice. A retrospective chart review of 123 PMR patients
referred to a tertiary care rheumatology clinic in Canada
demonstrated that the accuracy of PMR diagnosis by
non-rheumatologists was very low (24%), and that a large
number of inappropriate tests were performed by non-
rheumatologists in an eVort to reach diagnosis [22]. It is
therefore important for general practitioners to understand
epidemiological characteristics of PMR in addition to diag-
nose the disease accurately. Based on this evidence, the
present study was performed to clarify the rate of Japanese
patients with PMR or RS3PE syndrome in a clinic where
primary care physicians are working in Japan.
Patients and Methods
We analyzed consecutive outpatients who newly visited at
Department of General Medicine, Asahikawa Medical Uni-
versity Hospital between April 2004 and March 2010. As
we have recently demonstrated [23, 24], the hospital con-
sists of 602 beds in which approximately 250 doctors are
working to cover almost all of the medical problems.
Among them, 5 or 6 primary care physicians are working at
the Department of General Medicine. All data were drawn
from medical records and computerized physician order
entry system in the hospital. Each parameter such as age,
sex, and diagnosis was investigated from the source.
PMR was diagnosed according to the previous reports
[14, 25, 26]. They fulWlled the following clinical and labo-
ratory conditions; age older than 50; suVering from severe
myalgia and/or stiVness of bilateral neck, shoulders and
pelvic girdle for at least 2 weeks; bilateral upper arm ten-
derness; a marked increased erythrocyte sedimentation rate
(ESR > 50 mm/h). Normal serum creatinine kinase (CK)
concentration, and negative for rheumatoid factor (RF) and
antinuclear factor (ANA), and a dramatic response to low
doses of corticosteroid are observed. According to a previ-
ous report [27], patients were included as RS3PE syndrome
if they were older than 50 and satisWed the following diag-
nostic criteria: symmetrical polyarthritis, pitting edema of
the bilateral hands and foots, serological absence of RF,
and a fast response to steroid therapy.
Results
Out of 6,868 patients, PMR or RS3PE syndrome was diag-
nosed in 10 (0.15%) or 3 (0.04%) patients, respectively.
Table 1 shows the clinical characteristics of 10 patients with
PMR in this study. The patients with PMR ranged from 58
to 82 years old, and were 7 women and 3 men. The average
age at diagnosis was 69 years old. All patients had suVered
from severe myalgia in at least two parts of the body includ-
ing the neck, shoulders, and pelvic girdle. The myalgia had
persisted for 1–4 months. ESR at initial phase was over
50 mm/h in all patients. RF was negative in all 10 cases.
They responded well to PSL at doses of 5–15 mg/day.
On the other hand, RS3PE syndrome was diagnosed in 3
men (76, 76, and 81 years old) in this study. Female
patients with RS3PE syndrome have never observed in this
analysis. Onset of appearance of edema in extremities with
myalgia was sudden in all patients. Clinical characteristics
of 3 patients with RS3PE syndrome are showed in Table 2.
CRP level was elevated in all cases. However, ESR was
high in two cases (No1 and No.2) but normal in one case
(No.3). Two patients (No. 1 and No. 3 in Table 2) were ini-
tially treated with 20 or 15 mg/day of PSL. The response to
the dose of PSL was excellent in the two cases within Wrst
week. On the other hand, PSL at the dose of 30 mg was not
eVective in a patient (No. 2). The patient (No. 2) had been
Table 1 Clinical characteristics of 10 patients with polymyalgia
rheumatica (PMR)
PSL predonisolone
Age Gender Symptom 
duration 
(months)
WBC 
(/mm3)
CRP 
(mg/dl)
ESR 
(mm/h)
PSL 
dose (mg)
69 F 1 7,690 1.18 85 5
82 F 2 9,520 15.35 87 5
76 M 3 5,030 5.1 85 10
58 F 4 6,100 10.3 98 15
68 M 1 5,550 3.53 84 15
70 F 5 8,210 4.89 79 5
58 F 1 10,870 5.95 94 10
73 F 2 6,180 8.66 94 10
75 F 1 6,010 4.15 91 15
67 M 2 6,840 0.67 56 15Rheumatol Int (2012) 32:1695–1699 1697
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diagnosed as prostate cancer approximately 10 years ago by
a doctor in other hospital. He would die 1 year later after
the Wrst visit to our clinic because of bone metastasis from
prostate cancer, suggesting that the paraneoplastic factor-
induced RS3PE [28, 29] in this case might explain the ste-
roid resistance observed.
Table 3 demonstrates the distribution of age and sex in
patients with PMR or RS3PE syndrome in this study. Out
of all patients aged over 50, the rate of PMR was 0.22% in
men or 0.36% in women, respectively. The rate of patients
with RS3PE syndrome was 0.09% among general popula-
tion aged over 50. When compared with PMR, the rate of
RS3PE syndrome was approximately one-third.
Discussion
The only population-based study of PMR is from Olmsted
County, Minnesota, USA, where the prevalence of PMR is
given from cumulative incidence rates [8, 9]. Among per-
sons aged over 50, the prevalence of PMR was 739 per
100,000. Bernatsky et al. [10] have estimated that the prev-
alence of PMR in Manitobans, Canada, aged over 50 would
be approximately 641 cases per 100,000 in urban area and
864 cases per 100,000 in rural areas. These are compatible
with the Olmsted County data. In this study, out of 3,347
outpatients aged over 50, 10 patients were diagnosed as
PMR, estimating for the Wrst time the rate of PMR is
approximately 300 per 100,000, suggesting that the preva-
lence of PMR estimated in Japan is not so far from those in
USA and Canada.
Previous studies have shown that women are aVected
two times more often than men [30–32]. The present study
revealed that the rate of PMR was 0.22% in men or 0.36%
in women, respectively, indicating 1.6 times higher preva-
lence in women. The gender diVerence in Japan observed in
this study furthermore supports the previous evidence
observed in western countries that PMR is more frequently
in women than men. The average age at diagnosis was 69 in
this study, being in good agreement with the previous
evidence that the mean age at diagnosis of PMR was
approximately 70 years old [30–32].
To our knowledge, there is no evidence on the preva-
lence of RS3PE syndrome in not only Japan but also other
countries. Based on this study, the rate of patients with
RS3PE syndrome in Japan was 0.09% among outpatients
aged over 50. When compared with PMR, the rate of
RS3PE syndrome was approximately one-third. However,
the number of patients with RS3PE syndrome is quite small
in this study, thereby suggesting that a much larger survey
should be performed to more accurately estimate the preva-
lence of RS3PE syndrome in future.
Paira et al. have demonstrated that patients presented
clinical characteristics suggestive of paraneoplastic RS3PE
had a poor response to corticosteroid therapy [29]. In
patients with RS3PE, the presence of systemic symptoms
Table 2 Clinical characteristics of 3 patients with remitting seroneg-
ative symmetrical synovitis with pitting edema (RS3PE)
* This patient did not respond to PSL probably because of paraneoplas-
tic (prostate cancer) factor-induced disease
PSL predonisolone
No. Age Gender Symptom 
duration 
(months)
WBC 
(/mm)
CRP 
(mg/dl)
ESR 
(mm/h)
PSL 
dose (mg)
1. 76 M 2 6,580 5.1 61 20
2. 82 M 1 8,750 9.82 88 30*
3. 76 M 2 6,690 0.47 4 15
Table 3 Age and gender distribution of patients with PMR and
RS3PE
Age (A) Patients (B) PMR (B/A) 
(%)
(C) RS3PE (C/A) 
(%)
Male
0– 44 0 0
10– 166 0 0
20– 471 0 0
30– 479 0 0
40– 299 0 0
50– 406 0 0
60– 440 2 0.45 0
70– 389 1 0.26 2 0.51
80– 141 0 1 0.71
0–49 1,459 0 0
50– 1,376 3 0.22 3 0.22
Overall 2,835 3 0.11 3 0.11
Female
0– 22 0 0
10– 232 0 0
20– 692 0 0
30– 687 0 0
40– 430 0 0
50– 593 2 0.34 0
60– 589 1 0.17 0
70– 530 3 0.57 0
80– 258 1 0.39 0
0–49 2,062 0 0
50– 1,971 7 0.36 0
Overall 4,033 7 0.17 0
Both
0–49 3,521 0 0
50– 3,347 10 0.30 3 0.09
Total 6,868 10 0.15 3 0.041698 Rheumatol Int (2012) 32:1695–1699
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along with resistance to low doses of corticosteroid therapy
as shown in the present study (No. 2 in Table 2) should
alert the physician to the possible presence of malignancy.
In fact, the present patient who did not respond to steroid
had advanced prostate cancer. Although the serum level of
vascular endothelial growth factor (VEGF) or the expres-
sion of VEGF in the prostate cancer cells was not examined
in this study, we would speculate that increased expression
of VEGF in the prostate cancer cells might play a role in the
key molecule that induces RS3PE syndrome in the No. 2
patient in this study as following. A couple of reports
demonstrated that prostate cancer cells overexpress VEGF
[33–36] and overexpression of VEGF increases growth and
alters the metastatic potential of prostate cancer cells [37].
Recent evidence has suggested that VEGF may be impli-
cated in the pathogenesis of RS3PE syndrome [21]. These
results suggest that VEGF produced by prostate cancer
cells is capable of inducing not only tumor development but
RS3PE syndrome including pitting edema in the present
case (No. 2).
In conclusion, the present study demonstrated that out of
3,347 consecutive outpatients aged over 50, 10 (0.3%) or 3
(0.09%) patients were diagnosed as PMR or RS3PE syn-
drome, respectively, in an outpatient clinic where primary
care physicians are working in Japan. This epidemiological
evidence might help us understand the characteristics of the
diseases in primary care setting in Japan.
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tive Commons Attribution Noncommercial License which permits any
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